As of September 29, 2026, Galectin Therapeutics's top three insider holders are Richard E Uihlein (Director, 44.71Mn shares), Richard E Uihlein (Director, 10.33Mn shares), James C Czirr (TenPercentOwner, 5.92Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Richard E Uihlein | Director, TenPercentOwner | 0 | 44,713,843 | 44,713,843 | 78.0% | 04 Aug, 2026 |
| 2 | James C Czirr | TenPercentOwner | 0 | 5,922,207 | 5,922,207 | 10.3% | 25 Apr, 2024 |
| 3 | Fund, L.P. 10X | TenPercentOwner | 5,670,138 | 0 | 5,670,138 | 9.9% | 08 Dec, 2025 |
| 4 | Joel Lewis | President And Ceo | 776,260 | 0 | 776,260 | 1.4% | 13 Jan, 2026 |
| 5 | Kary Eldred | Director | 65,682 | 0 | 65,682 | 0.1% | 09 Feb, 2026 |
| 6 | Kevin D Freeman | Director | 55,269 | 0 | 55,269 | 0.1% | 23 Dec, 2025 |
| 7 | Richard A. Jr. Zordani | Director | 42,083 | 0 | 42,083 | 0.1% | 26 Dec, 2024 |
| 8 | Harold H. Shlevin | Chief Executive Officer | 37,329 | 0 | 37,329 | 0.1% | 30 Jun, 2026 |
| 9 | Jack W Callicutt | Chief Financial Officer | 22,842 | 0 | 22,842 | 0.0% | 06 Jan, 2026 |
| 10 | Khurram Jamil | Chief Medical Officer | 21,446 | 0 | 21,446 | 0.0% | 06 Jan, 2026 |
| 11 | Elissa J. Schwartz | Director | 1,000 | 0 | 1,000 | 0.0% | 24 Jan, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 31 Jul, 2026 | Richard E Uihlein | Director, TenPercentOwner | Acquired M | 31,825,235 | $3.00 | $95.48Mn | 42,162,911 | Indirect |
| 31 Jul, 2026 | Richard E Uihlein | Director, TenPercentOwner | Acquired M | 2,550,932 | $4.05 | $10.33Mn | 44,713,843 | Indirect |
| 14 Jul, 2026 | Khurram Jamil | Chief Medical Officer | Acquired M | 16,250 | $3.04 | $49.40K | 16,250 | Direct |
| 14 Jul, 2026 | Khurram Jamil | Chief Medical Officer | Disposed S | 16,250 | $5.13 | $83.28K | 0 | Direct |
| 14 Jul, 2026 | Khurram Jamil | Chief Medical Officer | Disposed M | 16,250 | $0.00 | $0 | 48,750 | Direct |
| 26 Jun, 2026 | Harold H. Shlevin | Director | Acquired M | 7,732 | $1.23 | $9.51K | 14,232 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Acquired M | 2,037 | $2.20 | $4.48K | 2,037 | Direct |
| 26 Jun, 2026 | Harold H. Shlevin | Director | Disposed S | 7,732 | $5.00 | $38.66K | 6,500 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed S | 2,037 | $5.00 | $10.19K | 0 | Direct |
| 29 Jun, 2026 | Harold H. Shlevin | Director | Acquired M | 22,268 | $1.23 | $27.39K | 28,768 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Acquired M | 2,533 | $2.50 | $6.33K | 2,533 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed S | 2,533 | $5.00 | $12.67K | 0 | Direct |
| 29 Jun, 2026 | Harold H. Shlevin | Director | Disposed S | 22,268 | $5.04 | $112.23K | 6,500 | Direct |
| 26 Jun, 2026 | Harold H. Shlevin | Director | Disposed M | 7,732 | $0.00 | $0 | 52,268 | Direct |
| 29 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Acquired M | 47,467 | $2.50 | $118.67K | 47,467 | Direct |
| 29 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed S | 47,467 | $5.04 | $239.23K | 0 | Direct |
| 29 Jun, 2026 | Harold H. Shlevin | Director | Disposed M | 22,268 | $0.00 | $0 | 30,000 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed M | 2,037 | $0.00 | $0 | 100,000 | Direct |
| 26 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed M | 2,533 | $0.00 | $0 | 47,467 | Direct |
| 29 Jun, 2026 | Khurram Jamil | Chief Medical Officer | Disposed M | 47,467 | $0.00 | $0 | 0 | Direct |